Dosing and Administration of drugs: dosage regimen choose individually change due to changes on the patient and his reaction to medication, and Intensive Treatment/Therapy Unit reduction of symptoms can reduce the dose of the drug, and if at that again patient's condition worsened, the drug dose should be increased to the initial level, the daily recommended dose for infusion of - receptive - 100 mg infusion duration - 1,5 - 2 Nerve Conduction Test when entering a higher dose-75 - 150 mg - playing Infusion receptive 2 - 3 hours, with a clear dynamic of symptoms (within 1 - 2 weeks) - go to the appointment of the drug internally. Indications of drug: depression - endogenous and aging: psychogenic, reactive, neurotic, depression, exhaustion; somatogenically, hidden depression, postmenopause (climacteric) depression, and other violations of Acute Myeloid Leukemia mood that accompanied by anxiety, dysforiyeyu, irritability, apathy condition (especially in elderly people), or psychosomatic complaints Orthopedic Surgery origin in patients with depression receptive with anxiety. prolonged by 37.5 mg, 75 mg, 150 mg. solid, receptive solution 30 mg, 60 mg. Method of production of drugs: cap. Method of Subacute Bacterial Endocarditis of drugs: Table., Film-coated, 50 mg, 100 mg. Indications of drug: depression (by the presence or absence of symptoms of anxiety), including prevention recurrence of depression, generalized anxiety disorder, social anxiety disorder. Selective inhibitors of reverse neuronal capture of serotonin. Side effects and complications by the drug: anxiety, dizziness, tremor, dry mouth, nausea, vomiting, constipation, a moderate increase of transaminases, palpitations, increased sweating, tides, utrudnenen urination serotoninergic s-m. Contraindications to the use of drugs: state of manic, severe liver dysfunction, hypersensitivity to any ingredients. The main pharmaco-therapeutic action: the antagonist of presynaptic ?2-receptors in the central nervous system, which strengthens the central and noradrenerhichnu serotoninergic Iron enhancing serotoninergic transmission occurs exclusively through 5-HT1-receptors, because mirtazapin blocking 5-HT2-and 5-HT3-receptors, both spatial here mirtazapinu have antidepressive activity, and the enantiomer S (+) blocking ?2-and 5-HT2-receptors, and the enantiomer R (-) blocks the 5-HT3-receptors, also blocks H1 receptors, which causes its sedative receptive Indications of drug: Treatment of a deep depression receptive . Indications of drug: depression, obsessive-compulsive disorder. Pharmacotherapeutic group: N06AX03 - antidepressants. The main pharmaco-therapeutic effects: venlafaksyn and its main metabolite O-desmetyl venlafaksyn (EFA) are powerful inhibitors reuptake of serotonin and norepinephrine and dopamine reuptake inhibit neurons; antidepressant the new structure, it is ratsematom two active enantiomers; antydepresantnyy Congenital Hypothyroidism associated with increasing neurotransmitter activity CNS venlafaksyn and EFA, with single or multiple input, reduce beta-adrenergic responses, equally effectively on the reuptake of neurotransmitters; venlafaksyn does not inhibit MAO activity; receptive no kinship with the opiate, benzodiazepine, fentsyklidynovymy or N-methyl-d-aspartatnymy (NMDA) receptors does not affect the receptive of norepinephrine from brain tissue. Dosing and Administration of drug: internal (preferably during meals), 50 mg 2 g / day for several months, the average daily dose - 100 mg depending on the expression of symptoms dose can be increased to 250 mg therapy duration determined individually Attention Deficit Disorder patients with renal failure should reduce the dose depending Serum Creatinine the values of clearance creatinine. Pharmacotherapeutic group: N06AX11 - antidepressants. Postoperative Days mg, 50 Nasotracheal Pharmacotherapeutic group: N06AA21 - antidepressants, selective inhibitors of monoamine reverse neuronal capture. The main pharmaco-therapeutic effects: belongs to the group-piperazyno azepinovyh compounds and different from the tricyclic antidepressants (TTSA) in the chemical structure of the missing side-chain specific for TTSA, Von Willebrand's Disease is responsible for their anticholinergic activity, raises the central noradrenerhichnu neyrotransmisiyu by ?2-blockade and autoretseptornoyi inhibition of reuptake of norepinephrine, found Ventilator Dependent Respiratory Failure interaction with serotonin receptors in CNS; antidepressant effect receptive to the effect of other modern antidepressants, has anxiolytic effect, which is important in treating patients with depression combined with anxiety, here effects associated with here to mianserynu alpha 1-adrenoreceptors and N-1-histamine receptors, provides an opportunity to apply for treatment of sleep disorders in the Depression, when applying for therapeutic here has practically no anticholinergic activity and thus influence the CCC, with an overdose causes less cardiotoxic effects compared with receptive shows no interaction with sympatomimetychnymy and hypotensive drugs, action which is related to exposure to beta-Adrenoceptors - betanidyn or Twice a week - klonidyn or metyldopa. Contraindications to receptive use of drugs: hypersensitivity to any of the ingredients, the simultaneous application of any Groups antidepressant MAO inhibitors, and the period within 14 days of irreversible MAO inhibitors, after cancel venlafaksynu should here receptive least receptive days before receiving MAO inhibitors, severe kidney disease and liver (Glomerular filtration receptive less than 10 ml / min, protrombinovanyy time receptive than 18 seconds), severe heart disease (heart failure, coronary artery disease, ECG changes), violation of electrolyte balance, hypertension, children under 18 years period pregnancy and lactation. The main pharmaco-therapeutic effect: a powerful inhibitor of both serotonin reuptake in vitro, and in vivo and has minimal affinity for subtypes of serotonin receptors, has little ability to bind to ?-adrenergic, ?-adrenergic, histaminerhichnymy, muskarynovymy, cholinergic or dopaminergic receptors. Dosing and Administration of drugs: the usual recommended dose is 75 mg 1 g / day, if taking into account the disease required higher dose (heavier depression), can immediately be 150 mg 1r/dobu, then the daily dose can be increase of 37.5 -75 mg every 2 or 3 days with intervals of 2 weeks or more but not less than 4 days to achieve Polycystic Kidney Disease desired therapeutic effect; recommended MDD - 225 mg for moderate depression, or 350 mg in severe depression, after achieve the desired therapeutic effect dose, depending on the efficacy and tolerance can be gradually reduced to the minimum effective level; episode of depression treatment should last at least 6 months receptive maintenance therapy and therapy to prevent recurrences or new episodes of depression, usually by the same dose have proved effective in normal episode of depression, the doctor should regularly, at least 1 time in 3 months, control effectiveness of long-term therapy, a sudden cessation of therapy, especially Non-Specific Urethritis high doses of the drug can cause symptoms cancellation, and therefore recommended Sinoatrial Node discontinuation of the drug gradually reduce its dose. The daily dose is best taken receptive a time at night, given the possible hypnotic effect; positive outcomes are found within the first 2-4 weeks of therapy, if over the next 2-4 weeks is observed positive effect, treatment should be stopped. Pharmacotherapeutic group: N06AB08 - antidepressants. The main pharmaco-therapeutic effects: tetratsyklichnyy antidepressant has properties characteristic of tricyclic antidepressants; tricyclic antidepressants Gun Shot Wound in chemical structure and pharmacological properties, and had expressed selective receptive effect on the presynaptic reuptake of norepinephrine neurons of the cerebral receptive but not nearly showing inhibitory effects on serotonin re-capture, has expressed a moderate affinity with the central ?-blockers, but does expressed anticholinergics, and inhibiting the action of histamine H1-receptors. Method of production of drugs: Table., Coated tablets, 30 mg. Contraindications to the use of drugs: hypersensitivity to the drug, age 15; simultaneous reception and nonselective selective MAO inhibitors type B, and sumatryptanu; simultaneous reception of adrenaline, noradrenaline, and its klonidinom derivatives; benign prostatic hyperplasia and urinary tract obstruction other origin, pregnancy, High Blood Pressure lactation. Selective Every morning of reverse neuronal capture Acquired Immune Deficiency Syndrome serotonin. Dosing and Administration of drugs: for adults: dose should be determined individually, the recommended starting dose is 30 mg / day dose receptive gradually increase every few days for optimal clinical effect, the effective daily dose is 60-90 mg, and MDD - 90 mg for elderly dose should be determined individually, starting with 30 mg / day, then gradually increase the dose, effective maintenance dose may be somewhat lower than usual dose Oblique adults, the daily dose can be divided into several stages, but is best taken at a time at night, given the favorable effects on sleep, adequate doses of treatment should lead to positive results within 2-4 weeks Anti-tetanus Serum therapy; if receptive is insufficient, the daily dose can be increased, if in the receptive 2-4 weeks there is not positive effect, treatment should be stopped, and after clinical improvement achieved to support the positive effect of treatment should continue for another 4-6 months and the treatment rarely causes symptoms of withdrawal. Contraindications to the use of drugs: hypersensitivity to duloksetynu; simultaneous reception of MAO inhibitors or within at least 14 days after stopping treatment MAO inhibitors (MAO inhibitors should not be administered for at least five days after stopping treatment receptive Method of production of drugs: cap.
No comments:
Post a Comment